The Protocol Review Committee (PRC) of University of Pittsburgh Cancer Institute (UPCI) is responsible for reviewing all clinical cancer research studies conducted at the University of Pittsburgh and UPMC prior to initiation of the study. Its activities are overseen by the Clinical Research Oversight Committee (CROC) along with two other entities that work in parallel to orchestrate cancer clinical research, the Data Safety and Monitoring Committee (DSMC) and the Clinical Research Services (CRS). The PRC also works in conjunction with three other parts of the clinical trials enterprise, the University of Pittsburgh IRB, the UPCI Biostatistics Facility, and the disease-oriented management teams, to promote the highest scientific quality and most efficient conduct of cancer clinical trials at the UPCI. The PRC is comprised of three committees. Committees A and B each meet once a month in order to facilitate prompt review of cancer treatment protocols. Committee C is responsible for reviewing all behavioral, cancer epidemiology, cancer prevention and control, and complementary medicine protocols as the need arises. The PRC evaluates each protocol to ensure appropriate study design and scientific quality and availability of patient and fiscal resources required for successful completion of the trial proposed. Membership of the PRC includes a diverse group of cancer experts including hematology/oncology, surgical oncology, urologic oncology, pharmacology, biostatistics, nursing, regulatory affairs, and laboratory scientists. PRC approval of cancer clinical trials is required before the study can be submitted to the University of Pittsburgh IRB. All UPCI trials are reviewed for accrual every six months. Studies achieving less than 30% of target accrual are flagged for review. A notification letter is sent to the PI requesting a plan to increase accrual, and the study is re-reviewed for accrual in six months. To simplify documentation and monitoring of UPCI clinical trials activities, all formal committees (PRC, CROC and three DSMC) have a single recording secretary, who is responsible for recording the minutes of each meeting, and facilitates communication between the committees, University and UPMC regulatory committees, regulatory agencies, and UPCI Pis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-24
Application #
8382695
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$125,600
Indirect Cost
$78,573
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358

Showing the most recent 10 out of 1187 publications